Natasha E. Daughtrey

Natasha E. Daughtrey

Associate
Natasha E. Daughtrey

Natasha Daughtrey is an associate in the firm’s Litigation Department and a member of its Intellectual Property Group. Ms. Daughtrey is a key contributor to Goodwin’s Founders Workbench, an online resource for start-ups, emerging companies and the entrepreneurial community. She joined Goodwin in 2011.

Professional Experience

Prior to joining Goodwin, Ms. Daughtrey was a Make a Difference Fellow at Brooklyn Legal Services Corporation A in the Individual Housing Unit where she represented tenants and tenant associations in housing litigation and appeals.

During law school, Ms. Daughtrey worked as a judicial intern to the Honorable Ronald M. Whyte, U.S. District Court for the Northern District of California and as a legal intern with the U.S. Attorney’s Office for the Southern District of California in the Civil Division. She was a member of San Diego Law Review

Ms. Daughtrey is a member of the New York City Bar Association Patents Committee, and a member of the New York Intellectual Property Law Association.

Areas of Practice

Experience

Ms. Daughtrey focuses her practice on intellectual property litigation and counseling. Ms. Daughtrey has experience representing companies in all stages of patent litigation  from pre- suit investigation through trial and appeal. She also advises clients on patent-related due diligence.

Representative matters include:

  • Genzyme Corporation, et al. v. Teva Pharmaceuticals USA, Inc., et al., No. 1:13-cv-01506 (D. Del.)

Representing Teva in an ongoing patent infringement litigation filed by Genzyme under the Hatch-Waxman Act in response to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of Genzyme’s stem cell mobilizing agent, Mozobil® (plerixafor).

  • Senju Pharmaceutical Co., Ltd., et al., v, Lupin Ltd., et al., No. 1:14-cv-6893 (D.N.J.)

Representing Lupin in an ongoing patent infringement litigation filed by Senju under the Hatch-Waxman Act in response to Lupin’s filing of an abbreviated new drug application seeking approval to market a generic version of Senju’s Prolensa® (bromfenac ophthalmic solution) medication. 

  • Glenmark Generics Ltd., et al. v. GlaxoSmithKline PLC, et al., No. 1:13-cv-00135 (D. Del.)

Representing Glenmark in a declaratory judgment action related to GlaxoSmithKline’s patents and Glenmark’s mupirocin cream.

  • Prometheus Laboratories Inc. v. Roxane Laboratories, Inc., et al., No. 2:11-cv-01241 (D.N.J.)

Representing Roxane in a patent infringement litigation filed by Prometheus in response to Roxane’s filing of an abbreviated new drug application seeking approval to market a generic version of Prometheus’s IBS treatment drug, Lotronex® (alosetron hydrochloride).  After a bench trial, the District Court found in favor of Roxane that Prometheus’s patent was invalid. 

  • Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., et al., No. 10-cv-01376 (S.D. Ind.)

Representing Teva and Fresenius in a patent infringement litigation filed by Lilly under the Hatch-Waxman Act in response to Defendants’ respective filings of abbreviated new drug applications seeking approval to market generic versions of Lilly’s mesothelioma and non-small cell lung cancer treatment drug, Alimta® (pemetrexed disodium).  The case is currently on appeal.

  • ViiV Healthcare UK Ltd. et al. v. Teva Pharmaceuticals USA, Inc., No. 11-576-RGA (D. Del.)

Representing Teva in patent infringement litigation filed by ViiV under the Hatch-Waxman Act in response to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of ViiV’s EPZICOM® (abacavir sulfate and lamivudine) drug products.

Credentials

Education

J.D., 2010
University of San Diego School of Law

(cum laude)

B.S., Biology, 2007
Arizona State University

Admissions

Bar

New York

Courts

U.S. District Court for the Southern District of New York
U.S. District Court for the Eastern District of New York
U.S. Court of Appeals for the Federal Circuit
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers